<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504946</url>
  </required_header>
  <id_info>
    <org_study_id>RNN-168-05-KE</org_study_id>
    <nct_id>NCT00504946</nct_id>
  </id_info>
  <brief_title>Pharmacological Modulations of Allergen-Specific Immunotherapy</brief_title>
  <official_title>The Effect of Glucocorticosteroid and Vitamin D3 Administration and Montelukast Treatment on Early Clinical and Immunological Effect of Allergen-Specific Immunotherapy in Asthmatic Children, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is mounting evidence that successful allergen immunotherapy (SIT) functions through the&#xD;
      induction of different subset of Treg including Foxp3 positive cells, therefore additional&#xD;
      strategies to enhance this property are highly attractive. Based on previous findings we&#xD;
      assumed that combine allergen immunotherapy with non-specific treatments such as&#xD;
      glucocorticosteroids and vitamin D3 as well as montelukast sodium treatment might enhanced&#xD;
      allergen tolerance induction and improved clinical effectiveness of allergen-specific&#xD;
      immunotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is mounting evidence that successful allergen immunotherapy (SIT) functions through the&#xD;
      induction of different subset of Treg including Foxp3 positive cells, therefore additional&#xD;
      strategies to enhance this property are highly attractive. Since corticosteroids directly&#xD;
      induce the development of an IL-10-synthesizing regulatory T-cell population (Tr1) and this&#xD;
      effect can be greatly increased with vitamin D3 treatment we , we assumed that combine&#xD;
      allergen immunotherapy with non-specific treatments such as glucocorticosteroids and vitamin&#xD;
      D3 as well as montelukast sodium treatment might enhanced allergen tolerance induction and&#xD;
      improved clinical effectiveness of allergen-specific immunotherapy, therefore we conducted&#xD;
      the stud comparing the effect of glucocorticosteroid, glucocorticosteroid with vitamin D3 or&#xD;
      montelukast sodium on early immunological and clinical effect of allergen-specific&#xD;
      immunotherapy in asthmatic children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regulatory T cell (CD4+CD25+Foxp3 positive) induction measured in peripheral blood mononuclear cells</measure>
    <time_frame>First visit, second visit (after 3 months) and third visit (after 12 months of immunotherapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine (IL-10, TGF-beta1, IL-4, IL-5, IL-13) determination in supernatants from peripheral blood mononuclear cells culture.</measure>
    <time_frame>First visit, second visit (after 3 months) and third visit (after 12 months of immunotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary card evaluation with asthma free days estimation, lung function measurement and analysis of reduction of the inhaled corticosteroids dose</measure>
    <time_frame>Visit first and third visit (after 12 months of immunotherapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:&#xD;
20mg prednisone+ 0.3mg lactose</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, colecalciferol, lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:&#xD;
20mg prednisone + 1000j colecalciferol + 0.3mg lactose</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:&#xD;
0.3mg lactose</description>
    <arm_group_label>III</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children &gt; 14 years old received 10mg oral tablet once daily at bedtime</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  allergic asthma with regular symptoms requiring long-term treatment with inhaled&#xD;
             corticosteroids&#xD;
&#xD;
          -  disease duration of at least 2 years&#xD;
&#xD;
          -  sensitisation only to house dust mites&#xD;
&#xD;
          -  resting FEV1 of more or equal 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  sensitization to allergens other than house dust mites&#xD;
&#xD;
          -  discontinuation of SIT from any reasons&#xD;
&#xD;
          -  need of a daily dose below 200 or above 800 mcg of budesonide or equivalent&#xD;
&#xD;
          -  other chronic disease including vitamin D3 deficiency and/or resistance which could&#xD;
             influence the results of the study or the patient's ability to participate in the&#xD;
             study as judged by the investigator&#xD;
&#xD;
          -  medications that resulted in patient exclusion included: inhaled long acting&#xD;
             β2-agonist, leukotriene modifiers, β-blockers (eye drops included) or oral&#xD;
             corticosteroids within 6 month before the pre-study visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paweł Majak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwona Stelmach, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Universtity of Lodz</name_title>
    <organization>Department of Pediatrics and Allergy</organization>
  </responsible_party>
  <keyword>allergen immunotherapy premedication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

